ME/CFS research at Haukeland University Hospital - Norway
Myalgic encephalomyelitis (ME), also known as ME/ CFS (chronic fatigue syndrome), is a complex condition with no known cause. It affects some 0.2 per cent of Norwegians.
Kavli Trust has been supporting work by cancer specialists Olav Mella and Øystein Fluge at Haukeland University Hospital in Bergen, Norway, since 2011.
Their hypothesis is that ME could be an autoimmune condition.
More about this project
-
Promising results from trial of cancer drug in ME/CFS
May 06, 2020
- But results should be interpreted with caution, according to researchers from Haukeland University Hospital.
-
No effect of cancer drug treatment in patients with ME/CFS
April 02, 2019
Results from a double-blind drug trial showed no effect of treatment with the cancer drug rituximab.
-
The Kavli Trust renews its support for ME research at Haukeland University Hospital
September 14, 2018
The Kavli Trust in Norway is continuing its long cooperation with the research group for ME/CFS at Haukeland University Hospital, supporting further biomedical research with NOK 4.72 million in 2018 and 2019.
-
Continued backing for ME work
June 26, 2017
The Kavli Trust is extending its collaboration over biomedical research on chronic fatigue syndrome or myalgic encephalopathy (ME) at Haukeland University Hospital in Bergen.
-
New study on pathological mechanisms in ME from Bergen research group
December 22, 2016
A new study, partly funded by the Kavli Trust, suggests that the PDH enzyme is inhibited in ME/CFS patients, which may explain both energy shortage and increased lactate production in these patients. These findings have now been published in the Journal of Clinical Investigation Insight.